Lymphoblastic lymphoma

Gautam Borthakur; Susan M. O'Brien

doi:10.1007/978-1-62703-408-1_15

Lymphoblastic lymphoma

Gautam Borthakur, Susan M. O'Brien

Leukemia

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Lymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia (ALL) are largely overlapping entities based on morphology, immunophenotype, and molecular aberrations. Arbitrary distinctions are made between these entities by the extent of marrow involvement. Juxtaposition of genes encoding oncogenic transcription factor to T-cell receptor genes, activating Notch mutations, and loss of tumor suppressors are common events in T-LBL. Adoption of ALL-like therapy and pediatric regimens has improved outcome in LBL. Treatments targeting Notch, mTOR/Akt pathways, etc. and newer nucleoside analogs are expected to improve outcome in LBL.

Original language	English (US)
Title of host publication	Lymphoma
Subtitle of host publication	Diagnosis and Treatment
Publisher	Humana Press Inc.
Pages	243-256
Number of pages	14
ISBN (Electronic)	9781627034081
ISBN (Print)	9781627034074
DOIs	https://doi.org/10.1007/978-1-62703-408-1_15
State	Published - Jan 1 2013

Keywords

Acute lymphoblastic leukemia
Lymphoblastic
Lymphoma

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-1-62703-408-1_15

Cite this

@inbook{a7999c2bec5c4d92b60f0ce1b9173288,

title = "Lymphoblastic lymphoma",

abstract = "Lymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia (ALL) are largely overlapping entities based on morphology, immunophenotype, and molecular aberrations. Arbitrary distinctions are made between these entities by the extent of marrow involvement. Juxtaposition of genes encoding oncogenic transcription factor to T-cell receptor genes, activating Notch mutations, and loss of tumor suppressors are common events in T-LBL. Adoption of ALL-like therapy and pediatric regimens has improved outcome in LBL. Treatments targeting Notch, mTOR/Akt pathways, etc. and newer nucleoside analogs are expected to improve outcome in LBL.",

keywords = "Acute lymphoblastic leukemia, Lymphoblastic, Lymphoma",

author = "Gautam Borthakur and O'Brien, {Susan M.}",

note = "Publisher Copyright: {\textcopyright} Springer Science+Business Media, LLC 2013.",

year = "2013",

month = jan,

day = "1",

doi = "10.1007/978-1-62703-408-1_15",

language = "English (US)",

isbn = "9781627034074",

pages = "243--256",

booktitle = "Lymphoma",

publisher = "Humana Press Inc.",

}

TY - CHAP

T1 - Lymphoblastic lymphoma

AU - Borthakur, Gautam

AU - O'Brien, Susan M.

N1 - Publisher Copyright: © Springer Science+Business Media, LLC 2013.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Lymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia (ALL) are largely overlapping entities based on morphology, immunophenotype, and molecular aberrations. Arbitrary distinctions are made between these entities by the extent of marrow involvement. Juxtaposition of genes encoding oncogenic transcription factor to T-cell receptor genes, activating Notch mutations, and loss of tumor suppressors are common events in T-LBL. Adoption of ALL-like therapy and pediatric regimens has improved outcome in LBL. Treatments targeting Notch, mTOR/Akt pathways, etc. and newer nucleoside analogs are expected to improve outcome in LBL.

AB - Lymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia (ALL) are largely overlapping entities based on morphology, immunophenotype, and molecular aberrations. Arbitrary distinctions are made between these entities by the extent of marrow involvement. Juxtaposition of genes encoding oncogenic transcription factor to T-cell receptor genes, activating Notch mutations, and loss of tumor suppressors are common events in T-LBL. Adoption of ALL-like therapy and pediatric regimens has improved outcome in LBL. Treatments targeting Notch, mTOR/Akt pathways, etc. and newer nucleoside analogs are expected to improve outcome in LBL.

KW - Acute lymphoblastic leukemia

KW - Lymphoblastic

KW - Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85032801117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032801117&partnerID=8YFLogxK

U2 - 10.1007/978-1-62703-408-1_15

DO - 10.1007/978-1-62703-408-1_15

M3 - Chapter

AN - SCOPUS:85032801117

SN - 9781627034074

SP - 243

EP - 256

BT - Lymphoma

PB - Humana Press Inc.

ER -

Lymphoblastic lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this